Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Abstract Text:

Robin DiFrancesco,Robert DiCenzo,Glorimar Vicente,Julie Donnelly,Troy M Martin,Luis A Colon,Giovanni Schifito,Gene D Morse,

A method for the determination of lopinavir (LPV) concentrations in cerebral spinal fluid (CSF) and plasma ultrafiltrate (UF) was developed and validated to analyze clinical specimens from patients receiving antiretroviral treatment with lopinavir/ritonavir. The CSF (400 microL sample volume) final calibration range for LPV was 0.313-25.0 ng/mL. The final calibration range for UF (50 microL sample volume) was 1.25-100 ng/mL. The samples were prepared using liquid-liquid extraction, concentrated, and analyzed using a reversed phase isocratic separation. Detection was achieved in positive mixed reaction monitoring mode on a triple quadrupole mass spectrometer. Isolation of LPV through chromatographic separation and proper selection of calibration matrix were important factors in achieving accurate results. Plasma UF was found to be an equivalent calibration matrix to CSF whereas plasma matrix produced a positive bias in samples with unknown concentrations. Artificial CSF media prepared chemically were biased and less superior than UF. Sources of plasma for the UF did not affect accuracy. Several CSF sources were tested for specificity of the method and LPV concentrations were accurately produced with atmospheric pressure chemical ionization source producing more accurate results than the electrospray source. The method successfully measured LPV concentrations in CSF that were previously undetectable by HPLC as well as UF from protein binding studies.

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Publishing Authors By Initials

R DiFrancesco,R DiCenzo,G Vicente,J Donnelly,TM Martin,LA Colon,G Schifito,GD Morse,

For similar natural sciences: time: time factors research abstracts see: natural sciences: time: time factors research

PUBMED ID PMID:

MEDLINE DATE:

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of pharmaceutical and biomedical analysis

VOLUME: 44

Page Numbers: 1139-46

Journal Abbreviation:

ISSN: 0731-7085

DAY: 25

MONTH: 05

YEAR: 2007

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8309336

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Keywords Mesh Terms:

KEYWORDS: Time Factors

MESH TERMS: methods

Chemical & Substance for Abstract: Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. Information

Substance Name: lopinavir

Registry Number: 192725-17-0

Grant and Affiliation Information for Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.

AFFILIATION: Department of Pharmacy Practice, University at Buffalo, NY 14260, United States. rda@buffalo.edu

Country: England

AGENCY: United States PHS

GRANT: SIORRR14572

ACRONYM: DA

MEDLINETA: J Pharm Biomed Anal

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry Related Publications

• A dinoflagellate AAA family member rescues a conditional yeast G1/S phase cyclin mutant through increased CLB5 accumulation.
• Advances in pharmacogenomics of antiretrovirals: an update.
• Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells.
• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
• Bone morphogenetic protein receptor 2 mutations in pulmonary hypertension.
• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
• Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
• Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.
• Direct selection of RNA beacon aptamers.
• Drug interactions between proton pump inhibitors and antiretroviral drugs.
• Duplicate publication.
• Effects of pyriproxyfen on California red scale (Hemiptera: Diaspididae) development and reproduction.
• Functional deficiency in IL-7 caused by an N-ethyl-N-nitrosourea-induced point mutation.
• Genome-wide analysis of transcriptional dependence and probable target sites for Abf1 and Rap1 in Saccharomyces cerevisiae.
• Global infectious disease surveillance and health intelligence.
• Global preparedness for public health emergencies.
• HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.
• Hierarchical assembly of the siliceous skeletal lattice of the hexactinellid sponge Euplectella aspergillum.
• High resolution Fourier-domain optical coherence tomography of retinal angiomatous proliferation.
• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
• Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
• Pandemic influenza: studying the lessons of history.
• Rotationally resolved spectroscopy of jet-cooled NbMo.
• Simulations of dynamics and viscoelasticity in highly entangled solutions of semiflexible rods.
• Technology evaluation: BLP-25, Biomira Inc.
• The US pandemic influenza implementation plan at six months.
• Toxicity of systemic neonicotinoid insecticides to avocado thrips in nursery avocado trees.
• Transcription factor access to promoter elements.
• Use of the finite element method to assess impact of current on forearm and wrist during an electrical accident.
• Wide dynamic range germanium detector for perturbation crystallography.